Clinical Perspectives of Theranostics

Theranostics covers combination of diagnostic and therapeutic techniques for various cancers throughout body using suitable drug combination. This review covers well-known treatment of thyroid cancer and pheochromocytoma with I-131 compounds and also new radiopharmaceuticals for prostatic cancer and pancreatic cancer. Of particular, new trends toward patient outcome has been focused. A recent clinical study highlighted the ability of alpha-radiotherapy with high LET to overcome treatment resistance to beta--particle therapy. The theranostics will become an ever-increasing part of clinical nuclear medicine these days.

Download Full-text

Clinical Perspectives of Theranostics

10.20944/preprints202102.0314.v1 ◽

2021 ◽

Author(s):

Nagara Tamaki ◽

Shozo Okamoto ◽

Tohru Shiga

Keyword(s):

Patient Outcome ◽

Pancreatic Cancer ◽

Nuclear Medicine ◽

Thyroid Cancer ◽

Drug Combination ◽

Prostatic Cancer ◽

Therapeutic Techniques

Theranostics covers combination of diagnostic and therapeutic techniques for various cancers throughout body using suitable drug combination. This review covers well-known treatment of thyroid cancer and pheochromocytoma with I-131 compounds and also new radiopharmaceuticals for prostatic cancer and pancreatic cancer. Of particular, new trends toward patient outcome has been focused. The theranostics will become an ever-increasing part of clinical nuclear medicine these days.

Download Full-text

Clinical Perspectives of Theranostics

Molecules ◽

10.3390/molecules26082232 ◽

2021 ◽

Vol 26 (8) ◽

pp. 2232

Author(s):

Shozo Okamoto ◽

Tohru Shiga ◽

Nagara Tamaki

Keyword(s):

Nuclear Medicine ◽

Treatment Resistance ◽

Emission Tomography ◽

Particle Therapy ◽

Beta Particle ◽

Non Hodgkin Lymphoma ◽

Diagnostic Nuclear Medicine ◽

Positron Emission ◽

Recent Clinical Study ◽

High Linear Energy Transfer

Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Furthermore, new radiopharmaceuticals for prostatic cancer and pancreatic cancer have been added. Of particular, F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) is often used for treatment monitoring and estimating patient outcome. A recent clinical study highlighted the ability of alpha-radiotherapy with high linear energy transfer (LET) to overcome treatment resistance to beta--particle therapy. Theranostics will become an ever-increasing part of clinical nuclear medicine.

Download Full-text

Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance

Cancers ◽

10.3390/cancers13143481 ◽

2021 ◽

Vol 13 (14) ◽

pp. 3481

Author(s):

Kendelle J. Murphy ◽

Cecilia R. Chambers ◽

David Herrmann ◽

Paul Timpson ◽

Brooke A. Pereira

Keyword(s):

Pancreatic Cancer ◽

Tumor Development ◽

Treatment Resistance ◽

Tumor Stroma ◽

Response To Treatment ◽

Ductal Adenocarcinoma ◽

Cell Phenotype ◽

Stromal Compartment ◽

Clinical Prognosis ◽

Functional Value

Many cancer studies now recognize that disease initiation, progression, and response to treatment are strongly influenced by the microenvironmental niche. Widespread desmoplasia, or fibrosis, is fundamental to pancreatic cancer development, growth, metastasis, and treatment resistance. This fibrotic landscape is largely regulated by cancer-associated fibroblasts (CAFs), which deposit and remodel extracellular matrix (ECM) in the tumor microenvironment (TME). This review will explore the prognostic and functional value of the stromal compartment in predicting outcomes and clinical prognosis in pancreatic ductal adenocarcinoma (PDAC). We will also discuss the major dynamic stromal alterations that occur in the pancreatic TME during tumor development and progression, and how the stromal ECM can influence cancer cell phenotype, metabolism, and immune response from a biochemical and biomechanical viewpoint. Lastly, we will provide an outlook on the latest clinical advances in the field of anti-fibrotic co-targeting in combination with chemotherapy or immunotherapy in PDAC, providing insight into the current challenges in treating this highly aggressive, fibrotic malignancy.

Download Full-text

Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts

Endocrine ◽

10.1007/s12020-020-02418-x ◽

2020 ◽

Vol 70 (2) ◽

pp. 280-291

Author(s):

Alfredo Campennì ◽

Daniele Barbaro ◽

Marco Guzzo ◽

Francesca Capoccetti ◽

Luca Giovanella

Keyword(s):

Nuclear Medicine ◽

Thyroid Cancer ◽

Clinical Practice ◽

Molecular Imaging ◽

Routine Clinical Practice ◽

Whole Body ◽

Neck Ultrasound ◽

Long Term Follow Up

Abstract Purpose The standard of care for differentiated thyroid carcinoma (DTC) includes surgery, risk-adapted postoperative radioiodine therapy (RaIT), individualized thyroid hormone therapy, and follow-up for detection of patients with persistent or recurrent disease. In 2019, the nine Martinique Principles for managing thyroid cancer were developed by the American Thyroid Association, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and European Thyroid Association. In this review, we present our clinical practice recommendations with regard to implementing these principles in the diagnosis, treatment, and long-term follow-up of patients with DTC. Methods A multidisciplinary panel of five thyroid cancer experts addressed the implementation of the Martinique Principles in routine clinical practice based on clinical experience and evidence from the literature. Results We provide a suggested approach for the assessment and diagnosis of DTC in routine clinical practice, including the use of neck ultrasound, measurement of serum thyroid-stimulating hormone and calcitonin, fine-needle aspiration, cytology, and molecular imaging. Recommendations for the use of surgery (lobectomy vs. total thyroidectomy) and postoperative RaIT are also provided. Long-term follow-up with neck ultrasound and measurement of serum anti-thyroglobulin antibody and basal/stimulated thyroglobulin is standard, with 123/131I radioiodine diagnostic whole-body scans and 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography suggested in selected patients. Management of metastatic DTC should involve a multidisciplinary team. Conclusions In routine clinical practice, the Martinique Principles should be implemented in order to optimize clinical management/outcomes of patients with DTC.

Download Full-text

Nuclear medical inpatient treatment in Germany

Nuklearmedizin ◽

10.3413/nukmed-0296 ◽

2010 ◽

Vol 49 (02) ◽

pp. 49-57 ◽

Cited By ~ 10

Author(s):

M. Dietlein ◽

C. Reiners ◽

R. Lorenz

Keyword(s):

Nuclear Medicine ◽

Thyroid Cancer ◽

Inpatient Treatment ◽

Radioiodine Therapy ◽

Main Diagnosis ◽

Medical Inpatient ◽

Iodine Prophylaxis ◽

Iodine Supply ◽

Quality Report ◽

Quality Reports

SummaryAll public licensed hospitals of Germany are obligated since 2004 to establish and to publish a structured biennial quality report. The aim of this study was to analyse the quality reports from 2008 of clinics with nuclear-medicine therapy ward and to investigate developments for the inpatient nuclear-medicine therapy by comparing the results with the quality reports of the years 2004 and 2006. Methods: All available structured quality reports of clinics with a nuclear-medicine therapy ward of the years 2004, 2006 and 2008 were evaluated. Results: The total number of inpatient treatment cases in 2008 amounted to 54 190 (2006: 54 884; 2004: 57 366). This corresponds to a decrease of 5.5% in comparison to 2004. The number of the therapy wards decreased at the same time to currently 117 (2006: 120; 2004: 124). Remarkable changes were found in the spectrum of the main diagnosis. Thus, the most frequent diagnosis with the ICD-code E05 (hyperthyroidism) decreased continuously from 37 747 treatments in 2004 and 34 764 in 2006 to 31 756 in the year 2008. In contrast, the ICD-diagnoses for thyroid cancer (C73, Z08) with 14 761 cases in 2008 increased with time (2006: 13 426; 2004: 12 581). Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism.

Download Full-text

Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome

Cancer Science ◽

10.1111/j.1349-7006.2008.00893.x ◽

2008 ◽

pp. ???-??? ◽

Cited By ~ 30

Author(s):

Satoshi Fujii ◽

Shuichi Mitsunaga ◽

Manabu Yamazaki ◽

Takahiro Hasebe ◽

Genichiro Ishii ◽

...

Keyword(s):

Patient Outcome ◽

Pancreatic Cancer ◽

Cancer Cells ◽

Pancreatic Cancer Cells ◽

Poor Patient ◽

Poor Patient Outcome

Download Full-text

Diagnostic Nuclear Medicine Investigations in the Management of Thyroid Cancer

Practical Management of Thyroid Cancer ◽

10.1007/1-84628-013-3_27 ◽

2006 ◽

pp. 341-357

Author(s):

Susan E.M. Clarke

Keyword(s):

Nuclear Medicine ◽

Thyroid Cancer ◽

Diagnostic Nuclear Medicine

Download Full-text

Advance in Pancreatic Cancer Diagnosis and Therapy

10.5772/intechopen.94413 ◽

2020 ◽

Author(s):

Xiaojie Cai ◽

Jie Gao ◽

Yanfang Liu ◽

Ming Wang ◽

Qiulian Ma ◽

...

Keyword(s):

Pancreatic Cancer ◽

Stem Cells ◽

Survival Rate ◽

Tumor Microenvironment ◽

Cancer Diagnosis ◽

Treatment Resistance ◽

Serum Markers ◽

Molecular Probes ◽

Cancer Death ◽

Cancer Diagnosis And Therapy

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

Download Full-text